Evaluation of serum neopterin levels in patients with Graves disease

Sinem Gürcü; Göknur Yorulmaz; Evin Kocatürk; Hatice Hamarat; Melisa Şahin Tekin; Yeşim Kaya Yaşar; İ. Özkan Alataş

Makale detayları

Evaluation of serum neopterin levels in patients with Graves disease

Yazarlar:

Sinem Gürcü | Göknur Yorulmaz | Evin Kocatürk | Hatice Hamarat | Melisa Şahin Tekin | Yeşim Kaya Yaşar | İ. Özkan Alataş

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Eczacılık Biyokimyası | Otoimmünite | Endokrinoloji

Dergi:

Journal of Medicine and Palliative Care Vol.4 Issue 5, pp.418-422

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001302581

pISSN:

2717-7505

Anahtar kelimeler:

Özet:

 Aim: Graves disease is a disease with an autoimmune basis in which the synthesis and release of thyroid hormone from the thyroid gland increases. Interferon-gamma IFN-γ released from activated T lymphocytes causes macrophages to produce neopterin NPT, increasing its concentration in serum and other body fluids. There is a relationship between NPT and the production of free oxygen radicals by these cells. In this study, it was aimed to measure serum NPT levels in individuals with Graves disease. Material and Method: The study included 13 newly diagnosed Graves patients neopterin levels were measured at the time of first diagnosis and at the 3rd month of treatment and 16 Graves patients who were followed up in endocrinology outpatient clinics for at least one year. NPT levels of 23 healthy individuals without any disease were taken as the control group. Free triiodothyronine T3, free thyroxine T4, thyroglobulin, and thyroid stimulating hormone TSH levels were measured in the blood samples of the participants. Results: Serum NPT levels were found to be higher in Graves patients compared to the control group 6.66 nmolL in newly diagnosed patients, 9.24 nmolL in patients at the 3rd month of treatment, 10.68 nmolL in patients followed for one year or more, 1.44 nmolL in the control group, respectively, p 0.05. Conclusion: Monitoring NPT levels in serum and other body fluids can be used to evaluate the diagnosis, prognosis, and treatment efficacy of autoimmune diseases. In addition, NPT can be suggested as a potential biomarker to determine disease stage, treatment efficacy, and immunological remission status, as well as the diagnosis of Graves disease.

 Aim: Graves disease is a disease with an autoimmune basis in which the synthesis and release of thyroid hormone from the thyroid gland increases. Interferon-gamma IFN-γ released from activated T lymphocytes causes macrophages to produce neopterin NPT, increasing its concentration in serum and other body fluids. There is a relationship between NPT and the production of free oxygen radicals by these cells. In this study, it was aimed to measure serum NPT levels in individuals with Graves disease. Material and Method: The study included 13 newly diagnosed Graves patients neopterin levels were measured at the time of first diagnosis and at the 3rd month of treatment and 16 Graves patients who were followed up in endocrinology outpatient clinics for at least one year. NPT levels of 23 healthy individuals without any disease were taken as the control group. Free triiodothyronine T3, free thyroxine T4, thyroglobulin, and thyroid stimulating hormone TSH levels were measured in the blood samples of the participants. Results: Serum NPT levels were found to be higher in Graves patients compared to the control group 6.66 nmolL in newly diagnosed patients, 9.24 nmolL in patients at the 3rd month of treatment, 10.68 nmolL in patients followed for one year or more, 1.44 nmolL in the control group, respectively, p 0.05. Conclusion: Monitoring NPT levels in serum and other body fluids can be used to evaluate the diagnosis, prognosis, and treatment efficacy of autoimmune diseases. In addition, NPT can be suggested as a potential biomarker to determine disease stage, treatment efficacy, and immunological remission status, as well as the diagnosis of Graves disease.

 Aim: Graves disease is a disease with an autoimmune basis in which the synthesis and release of thyroid hormone from the thyroid gland increases. Interferon-gamma IFN-γ released from activated T lymphocytes causes macrophages to produce neopterin NPT, increasing its concentration in serum and other body fluids. There is a relationship between NPT and the production of free oxygen radicals by these cells. In this study, it was aimed to measure serum NPT levels in individuals with Graves disease. Material and Method: The study included 13 newly diagnosed Graves patients neopterin levels were measured at the time of first diagnosis and at the 3rd month of treatment and 16 Graves patients who were followed up in endocrinology outpatient clinics for at least one year. NPT levels of 23 healthy individuals without any disease were taken as the control group. Free triiodothyronine T3, free thyroxine T4, thyroglobulin, and thyroid stimulating hormone TSH levels were measured in the blood samples of the participants. Results: Serum NPT levels were found to be higher in Graves patients compared to the control group 6.66 nmolL in newly diagnosed patients, 9.24 nmolL in patients at the 3rd month of treatment, 10.68 nmolL in patients followed for one year or more, 1.44 nmolL in the control group, respectively, p 0.05. Conclusion: Monitoring NPT levels in serum and other body fluids can be used to evaluate the diagnosis, prognosis, and treatment efficacy of autoimmune diseases. In addition, NPT can be suggested as a potential biomarker to determine disease stage, treatment efficacy, and immunological remission status, as well as the diagnosis of Graves disease.

 Amaç: Graves hastalığı tiroid bezinden tiroid hormonunun sentez ve salınımının arttığı otoimmün temelleri olan bir hastalıktır. Aktive edilmiş T lenfositlerinden salınaninterferon-gamma  IFN-γ, makrofajların neopterin NPT üretmesine ve bunun serum ve diğer vücut sıvılarındaki konsantrasyonunu artırmasına neden olur. NPT ile bu hücrelerin serbest oksijen radikalleri üretmesi arasında bir ilişki vardır. Bu çalışmada Graves hastalığı olan bireylerde serum NPT düzeylerinin ölçülmesi amaçlandı. Gereç ve Yöntem: Çalışmaya, 13 yeni tanı almış Graves hastası ilk tanı anında ve tedavinin 3. ayında neopterin düzeyi bakıldı ve endokrinoloji polikliniklerinde en az bir yıldır takip edilen 16 Graves hastası dahil edildi. Herhangi bir hastalığı olmayan 23 sağlıklı bireyin NPT düzeyleri bakılarak kontrol grubu olarak alındı. Katılımcıların kan örneklerinde serbest triiyodotironin T3, serbest tiroksin T4, tiroglobulin ve tiroid uyarıcı hormon TSH düzeyleri ölçüldü. Bulgular: Serum NPT seviyeleri Graves hastalarında kontrol grubuna göre daha yüksek bulundu sırasıyla yeni tanı alanlarda 6,66 nmolL:,tedavinin 3. Ayındaki hastalarda 9,24 nmolL:, bir yıl ve üzeri süredir takip edilen hastalarda 10,68 nmolL, kontrol grubunda 1,44 nmolL , p 0,05,. Sonuç: Serum ve diğer vücut sıvılarında NPT seviyelerinin izlenmesi, otoimmün hastalıkların tanısını, prognozunu ve tedavi etkinliğini değerlendirmede kullanılabilir. Ayrıca NPT, Graves hastalığının tanısının yanı sıra hastalık evresini, tedavi etkinliğini ve immünolojik remisyon durumunu belirlemek için potansiyel bir biyobelirteç olarak öne sürülebilir.

Makale detayları

Evaluation of serum neopterin levels in patients with Graves disease

Yazarlar:

Sinem Gürcü | Göknur Yorulmaz | Evin Kocatürk | Hatice Hamarat | Melisa Şahin Tekin | Yeşim Kaya Yaşar | İ. Özkan Alataş

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Eczacılık Biyokimyası | Otoimmünite | Endokrinoloji

Dergi:

Journal of Medicine and Palliative Care Vol.4 Issue 5, pp.418-422

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001302581

pISSN:

2717-7505

Neopterin

Graves disease

Hyperthyroidism

Cellular immunity

T helper cells.Neopterin

Graves hastalığı

Hipertiroidizm

Hücresel bağışıklık

Yardımcı T hücreleri.

Sayı

Makale detayları

Yazarlar: Sinem Gürcü | Göknur Yorulmaz | Evin Kocatürk | Hatice Hamarat | Melisa Şahin Tekin | Yeşim Kaya Yaşar | İ. Özkan Alataş

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Eczacılık Biyokimyası | Otoimmünite | Endokrinoloji

Dergi: Journal of Medicine and Palliative Care Vol.4 Issue 5, pp.418-422

Belge Tipi: Makale

Yayın Tarihi: 10/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001302581

pISSN: 2717-7505

Sayı

Yazarlar:

Sinem Gürcü | Göknur Yorulmaz | Evin Kocatürk | Hatice Hamarat | Melisa Şahin Tekin | Yeşim Kaya Yaşar | İ. Özkan Alataş

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Eczacılık Biyokimyası | Otoimmünite | Endokrinoloji

Dergi:

Journal of Medicine and Palliative Care Vol.4 Issue 5, pp.418-422

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001302581

pISSN:

2717-7505